耐受性
药理学
医学
兴奋剂
活性代谢物
前列腺素
恶心
内科学
受体
不利影响
药代动力学
作者
Nika Skoro‐Sajer,Iréne Lang
标识
DOI:10.1517/14656566.2014.876007
摘要
Introduction: Selexipag is a first-in-class orally available selective non-prostanoid IP receptor agonist. This review was based on a PubMed search and focuses on the potential role of selexipag in the treatment of pulmonary arterial hypertension (PAH).
科研通智能强力驱动
Strongly Powered by AbleSci AI